

Supplementary Materials

Figure S1. HPLC-DAD chromatograms of all obtained *Miromelum* extracts in 280 nm

Figure S2. HPLC-DAD chromatograms of EtOAc, EtOAc_A and EtOAc_B extracts in 280 nm

Figure S3. ¹H-NMR spectrum of microfalcrin (**1**) in CD₃OD

Figure S4. HSQC spectrum of microfalcrin (**1**) in CD₃OD

Figure S5. HMBC spectrum of microfalcrin (**1**) in CD₃OD

Figure S6. ¹H-NMR spectrum of microcoumaririn (**2**) in CD₃OD

Figure S7. HSQC spectrum of microcoumaririn (**2**) in CD₃OD

Figure S8. HMBC spectrum of microcoumaririn (**2**) in CD₃OD

Figure S9. ¹H-NMR spectrum of micromelosidester (**3**) in CD₃OD

Figure S10. HSQC spectrum of micromelosidester (**3**) in CD₃OD

Figure S11. HMBC spectrum of micromelosidester (**3**) in CD₃OD

Figure S12. Full scan MS and MS/MS spectra of peak 1 of Table 1

Figure S13. Full scan MS and MS/MS spectra of peak 3 of Table 1

Figure S14. Full scan MS spectrum of peak 4 of Table 1

Figure S15. Full scan MS and MS/MS spectra of peak 5 of Table 1

Figure S16. Full scan MS and MS/MS spectra of peak 6 of Table 1

Figure S17. Full scan MS spectrum of peak 7 of Table 1

Figure S18. Full scan MS and MS/MS spectra of peak 8 of Table 1

Figure S19. Full scan MS and MS/MS spectra of peak 9 of Table 1

Figure S20. Full scan MS and MS/MS spectra of peak 12 of Table 1

Figure S21. Full scan MS and MS/MS spectra of peak 14 of Table 1

Figure S22. Full scan MS and MS/MS spectra of peak 15 of Table 1

Figure S23. Full scan MS and MS/MS spectra of peak 16 of Table 1

Figure S24. Full scan MS and MS/MS spectra of peak 17 of Table 1

Figure S25. Full scan MS and MS/MS spectra of microfalcrin (**1**) in ESI(+)

Figure S26. Full scan MS spectrum of microcoumaririn (**2**) in ESI(+)

Figure S27. Full scan MS and MS/MS spectra of micromelosidester (**3**) in ESI(+)

Figure S28. Full scan MS spectrum of micromeloside A (**4**) in ESI(+)

Figure S29. Full scan MS spectrum of microminutin (**5**) in ESI(+)

Figure S30. Full scan MS spectrum of micromelin (**6**) in ESI(+)

Figure S31. Full scan MS and MS/MS spectra of micromarin B (**7**) in ESI(+)

Figure S32. Full scan MS and MS/MS spectra of micromarin A (**8**) in ESI(+)

Figure S33. Percentage of nitrite oxide production relative to control (LPS-induced); Resv: Resveratrol, Mmin: Microminutin (**5**), Mmar B: Micromarin B (**7**); MmEtOAc: EtOAc extract

Figure S34. Percentage of NFκB induction relative to control (TNF-α treated); Resv: Resveratrol, Mmin: Microminutin (**5**), Mmar B: Micromarin B (**7**); MmEtOAc: EtOAc extract

Figure S1. HPLC-DAD chromatograms of all obtained *Miromelum* extracts in 280 nm.




Figure S2. HPLC-DAD chromatograms of EtOAc, EtOAc_A and EtOAc_B extracts in 280 nm.




Figure S3. ^1H -NMR spectrum of microfalcrin (**1**) in CD_3OD .




Figure S4. HSQC spectrum of microfalcrin (**1**) in CD_3OD .




Figure S5. HMBC spectrum of microfalcirin (**1**) in CD₃OD.




Figure S6. ¹H-NMR spectrum of microcoumaririn (**2**) in CD₃OD.




Figure S7. HSQC spectrum of microcoumaririn (**2**) in CD₃OD.




Figure S8. HMBC spectrum of microcoumaririn (**2**) in CD₃OD.




Figure S9. ^1H -NMR spectrum of micromelosidester (**3**) in CD_3OD .




Figure S10. HSQC spectrum of micromelosidester (**3**) in CD_3OD .







Figure S11. HMBC spectrum of micromelosidester (**3**) in CD₃OD.**Figure S12.** Full scan MS (A) and MS/MS (B) spectra of peak 1 of Table 1.

Mf_EtOAc_4 #177 RT: 4.11 AV: 1 SB: 385 6.89-19.17, 0.10-5.56 NL:
 F: FTMS + p ESI Full ms [200.00-800.00]



(A)


Mf_EtOAc_4 #176 RT: 4.08 AV: 1 SB: 386 6.89-19.17, 0.10-5.56 NL:
 T: FTMS + p ESI d Full ms2 315.08@cid35.00 [75.00-330.00]



(B)


Figure S13. Full scan MS (A) and MS/MS (B) spectra of peak 3 of Table 1.

Mf_DCM_4 #229 RT: 5.20 AV: 1 NL: 1.44E6
F: FTMS + p ESI Full ms [200.00-800.00]



(A)

Mf_DCM_4 #228 RT: 5.18 AV: 1 NL: 1.38E6
T: FTMS + p ESI d Full ms2 357.10@cid35.00 [85.00-370.00]



(B)

Figure S14. Full scan MS spectrum of peak 4 of Table 1.

Mf_DCM_4 #251 RT: 5.69 AV: 1 NL: 1.13E7
F: FTMS + p ESI Full ms [200.00-800.00]







Figure S15. Full scan MS (A) and MS/MS (B) spectra of peak 5 of Table 1.


(A)





(B)

Figure S16. Full scan MS (A) and MS/MS (B) spectra of peak 6 of Table 1.


(A)



(B)

Figure S17. Full scan MS spectrum of peak 7 of Table 1.**Figure S18.** Full scan MS (A) and MS/MS (B) spectra of peak 8 of Table 1.


(A)



(B)


Figure S19. Full scan MS (A) and MS/MS (B) spectra of peak 9 of Table 1.

Mf: EtOAc_4 #271 RT: 6.30 AV: 1 SB: 385 6.89-19.17 , 0.10-5.56 NL:
 F: FTMS + p ESI Full ms [200.00-800.00]



(A)


Mf: EtOAc_4 #272 RT: 6.32 AV: 1 SB: 386 6.89-19.17 , 0.10-5.56 NL:
 T: FTMS + p ESI d Full ms2 315.08@cid35.00 [75.00-330.00]



(B)


Figure S20. Full scan MS (A) and MS/MS (B) spectra of peak 12 of Table 1.

Mf: EtOAc_4 #325 RT: 7.54 AV: 1 SB: 385 6.89-19.17 , 0.10-5.56 NL:
 F: FTMS + p ESI Full ms [200.00-800.00]



(A)


Mf: EtOAc_4 #326 RT: 7.56 AV: 1 SB: 386 6.89-19.17 , 0.10-5.56 NL:
 T: FTMS + p ESI d Full ms2 399.14@cid35.00 [95.00-410.00]



(B)


Figure S21. Full scan MS (A) and MS/MS (B) spectra of peak 14 of Table 1.

Mf_EtOAc_4 #353 RT: 8.17 AV: 1 SB: 385 6.89-19.17 , 0.10-5.56 NL:
 F: FTMS + p ESI Full ms [200.00-800.00]



(A)


Mf_EtOAc_4 #352 RT: 8.15 AV: 1 SB: 386 6.89-19.17 , 0.10-5.56 NL:
 T: FTMS + p ESI d Full ms2 399.14@cid35.00 [95.00-410.00]



(B)


Figure S22. Full scan MS (A) and MS/MS (B) spectra of peak 15 of Table 1.

Mf_DCM_4 #373 RT: 8.44 AV: 1 NL: 1.94E6
 F: FTMS + p ESI Full ms [200.00-800.00]




(A)


Mf_DCM_4 #374 RT: 8.46 AV: 1 NL: 1.28E5
 T: FTMS + p ESI d Full ms2 343.12@cid35.00 [80.00-355.00]




(B)

Figure S23. Full scan MS (A) and MS/MS (B) spectra of peak 16 of Table 1.


(A)




(B)

Figure S24. Full scan MS (A) and MS/MS (B) spectra of peak 17 of Table 1.


(A)



(B)

Figure S25. Full scan MS (A) and MS/MS (B) spectra of microfalconin (1) in ESI(+).

(A)



(B)




Figure S26. Full scan MS spectrum of microcoumaririn (2) in ESI(+).

Figure S27. Full scan MS (A) and MS/MS (B) spectra of micromelosidester (3) in ESI(+).

(A)



(B)






Figure S28. Full scan MS spectrum of micromeloside A (4) in ESI(+).

Figure S29. Full scan MS spectrum of microminutin (**5**) in ESI(+).**Figure S30.** Full scan MS spectrum of micromelin (**6**) in ESI(+).**Figure S31.** Full scan MS (A) and MS/MS (B) spectra of micromarin B (**7**) in ESI(+).

(A)



(B)



Figure S32. Full scan MS (A) and MS/MS (B) spectra of micromarin A (8) in ESI(+).**Figure S33.** Percentage of nitrite oxide production relative to control (LPS-induced); Resv: Resveratrol, Mmin: Microminutinin (5), Mmar B: Micromarin B (7); MmEtOAc: EtOAc extract.

Figure S34. Percentage of NF κ B induction relative to control (TNF- α treated); Resv: Resveratrol, Mmin: Microminutin (**5**), Mmar B: Micromarin B (**7**); MmEtOAc: EtOAc extract.

